Ethos Biosciences

Ethos Biosciences is a consolidated diagnostic tools and reagents company formed in 2018, bringing together the legacy operations and products of Exocell, Astral Diagnostics, American Bionostica, and others under a single brand. It leverages over 80 years of combined heritage to manufacture and supply high-quality, easy-to-use products for research and diagnostic laboratories globally. The company's business model is purely commercial, generating revenue through the sale of its established product portfolio to OEM clients and end-users in life sciences, veterinary, and clinical sectors. Its strategy is to be a leading provider for specialty diagnostic applications.

Integrated manufacturing and development expertise across multiple diagnostic modalities, including immunoassay (ELISA) development, stain & reagent formulation, lateral flow device (LFD) manufacturing, and custom synthesis.

Operates in highly competitive markets for life science reagents and diagnostic manufacturing, competing against giants like Thermo Fisher Scientific, Merck KGaA, and Danaher, as well as numerous specialized niche players. Differentiation is based on product quality, expertise in specialty indications, and a collaborative OEM service model.